Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma Meeting Abstract
| Authors: | Chapman, P. B.; Ascierto, P. A.; Schadendorf, D.; Grob, J. J.; Ribas, A.; Kiecker, F.; Dutriaux, C.; Demidov, L. V.; Lebbe, C.; Rutkowski, P.; Blank, C. U.; Gutzmer, R.; Millward, M.; Kefford, R.; Huang, Y.; Zhang, Y.; Squires, M.; Mookerjee, B.; Hauschild, A. |
| Abstract Title: | Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 482s |
| Language: | English |
| ACCESSION: | WOS:000411932203169 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.9526 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9526 -- Source: Wos |
